GenMark Diagnostics, Inc. (GNMK)

[biocqr]

GenMark Diagnostics target raised to $14 at Canaccord Genuity; on to the next leg of growth (11.14)

Canaccord raises their GNMK tgt to $14 from $12. Given mgmt's recent track record of executing, coupled with its long-term growth trajectory, firm believes GNMK merits trading at the upper end of the MDx peer group P/S multiple (5x-7x). Given the strong start to the flu season, GNMK should see good results from its RVP test. CDC indicated that 7.3% of all deaths resulted from pneumonia and influenza, crossing the "epidemic" threshold of 7.2%.


Read more: http://www.briefing.com/InPlayEq/InPlay/InPlayDual.htm#ixzz2I3SHr07T
Under Creative Commons License: Attribution
Follow us: @Briefingcom on Twitter | Briefingcom on Facebook